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ABSTRACT: 
Background: Treatment of Drug Resistant Tuberculosis has historically been centralised and 
this model of care has posed challenges in management of such patients. Prolonged time to 
treatment and potential risk for continued community and nosocomial transmissions, capacity 
at these sites and availability of human resources to treat the increasing numbers of DRTB 
patients has been among those challenges. WHO set out to improve all DRTB outcomes 
especially in countries where the burden is high. Decentralisation of DRTB care has shown to 
improve these outcomes in many settings.  
Objectives: The main aim of the study was to describe any Rifampicin-resistant TB treatment 
outcomes in an ambulatory care model and to assess predictors of unsuccessful outcomes. 
Survival times for unsuccessful treatment outcomes were also determined. A comparison of 
the treatment outcomes by HIV status was also assessed. 
Methods: A retrospective cohort review of 335 patients with any Rifampicin-resistant TB 
diagnosis between January 2010 and January 2014, at Charlotte Maxeke Johannesburg 
Academic hospital DR-TB focal point was conducted. Survival analysis was done for 
unsuccessful outcomes. Multivariable Cox regression models were used to determine 
predictors of mortality, default and overall unsuccessful outcomes. Differences in outcomes by 
HIV status were compared using Pearson’s chi-square 
Results: Of the 335 patients analysed, 14 (4.2%) patients were still on treatment, 64 (19.1%) 
were successfully treated [with 17 (5.1%) cured and 47 (14%) completed treatment]. 
Unsuccessful outcomes were seen in 122 (36.4%) of the patients [with 30 (9%) died and 92 
(27.5%) defaulted]. The remaining 135 (40.3%) patients were transferred out. There were no 
treatment failures in this cohort. Median survival time for unsuccessful outcomes was 3.2 
months (IQR:1.4 to 9.2). Median time to death and default were 4.6 months (IQR:0.9 to13.8) 
and 3 months (IQR:1.4 to 8.5) respectively. There was no statistical difference found in 
proportions of successful and unsuccessful outcomes between HIV co-infected and HIV 
negative patients. Overall predictors of unsuccessful outcomes were: confirmed RMR-TB 
(HR=8.5; 95% CI: 2.0-35.2; p=0.003) and unconfirmed Rifampicin-resistance diagnosed on 
GXP alone (HR=10.9; 95% CI: 2.6-44.8; p=0.001). There were no statistically significant 
predictors of mortality found in this study. Predictors of default were: confirmed RMR-TB 
(HR=15.9; 95% CI: 2.1-116.5; p=0.006) and unconfirmed Rifampicin-resistance diagnosed on 
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GXP alone (HR=17.2; 95% CI: 2.4-125.3; p=0.01). For a subgroup of HIV co-infected patients, 
being initiated on ART had 90% less hazards of defaulting (HR=0.1; 95% CI: 0.05-0.2; 
p=0.000). Age category >40 years also had 60% less hazards of defaulting in the HIV co-
infected patients. Patients co-infected with HIV had higher hazards of default if they were 
diagnosed as confirmed RMR-TB (HR=10.8; 95% CI: 1.4-84.1; p=0.023) and unconfirmed 
Rifampicin-resistance diagnosed on GXP alone (HR=10.6; 95% CI: 1.4-80.2; p=0.022).  Not 
initiated on ART was a predictor of unsuccessful outcome among HIV co-infected patients 
(HR=7.6; 95% CI: 4.1-14.1; p=0.000).  
Conclusion: Overall treatment outcomes were poor, with a low success rate (19.1%) and a 
high defaulter rate (27.5%).  Mortality was comparable with other studies. Predictors of 
unsuccessful outcomes were confirmed RMR-TB and Rifampicin-resistance diagnosis on GXP 
only. Being initiated on ART and age >40 years reduced odds of defaulting by 90% and 60% 
respectively among HIV co-infected patients. 
Key recommendations: The high defaulter rate within the first few months of treatment 
impacts negatively on the control of DRTB, hence efforts to improve this are needed. 
Addressing factors associated with defaulting is crucial in DRTB clinics to curb transmission 
of DRTB in the community. All patients diagnosed with a GXP need immediate confirmation 
by LPA and culture/DST.  
Key words: Rifampicin resistant TB, Drug Resistant TB Treatment outcomes, Ambulatory 
DRTB care, DRTB/HIV co-infection 
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1. CHAPTER 1: INTRODUCTION 
 
This chapter gives an overview of the burden of tuberculosis (TB) and drug-resistant TB (DR-
TB) in particular. It also outlines the rationale for the study and explores the literature of 
relevance to this study.  
1.1 Background 
There was an increasing trend in the number of reported cases of Drug Resistant (DR) 
Tuberculosis (TB) over the past few years. [1] The use of Gene XPert® MTB/RIF (GXP) 
approved for use by the World Health Organisation (WHO) has increased identification of DR-
TB cases. [2] In South Africa (SA), the management of DR-TB has historically been centralised 
and institutionalised, where the patients were treated only within these central TB facilities. 
The centralised TB care model proved to have several challenges, including delayed time to 
DR-TB treatment initiation leading to decreased coverage of treatment. This meant that 
transmission in the community continued due to the delay but also that nosocomial 
transmissions increased for those who were hospitalized.[2, 7] The SA government, due to these 
challenges, have since proposed decentralisation and deinstitutionalisation of DR-TB 
patients.[2] These efforts were to decrease the delay in starting treatment, to increase treatment 
coverage and reduce DR-TB transmissions.[1] Decentralised or community care models in 
South Africa and elsewhere have been shown to be feasible and reduced delays in treatment 
initiation and improved survival of DRTB patients. [2, 3, 22, 26, 30] 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) is one of the three central 
academic hospitals in the City of Johannesburg. Its outpatient DR-TB clinic is an urban 
decentralised site for the management of DR-TB in the City of Johannesburg, serving a very 
dense population with a high burden of TB and Human Immunodeficiency Virus (HIV) co-
infection. Patients were referred from the feeder hospitals and primary health care centres and 
from within the hospital wards and outpatient departments with DR-TB diagnosis. These 
patients were only referred for admission at the centralised TB hospital, Sizwe Tropical and 
Infectious Disease Hospital (STIDH) when diagnosed with XDRTB or whenever an admission 
was warranted. Patients referred with Rifampicin resistant Xpert® MTB/RIF results were 
started on MDRTB treatment immediately while waiting for confirmation with Line Probe 
Assay (LPA), culture and Drug Sensitivity Testing (DST) results. The outpatient clinic offered 
integrated TB, HIV and chronic management services, a model which has shown better 
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treatment outcomes. [8, 9, 13] All patients with unknown HIV status and negative status were 
offered counselling and voluntary HIV testing. Antiretroviral therapy (ART) was also offered 
within this outpatient clinic. MDRTB was defined as Mycobacterium TB resistance to 
Isoniazid (INH) and Rifampicin (R), according to WHO definition.[60]  Extensively drug 
resistant TB (XDRTB) was defined as the presence of MDR-TB plus resistance to any of the 
fluoroquinolones and any one of the second-line anti-tuberculous injectable drugs Amikacin 
(AM), Kanamycin (KM) and Capreomycin (CM).[60] In the clinic treatment for MDRTB was 
administered for 18 to 24 months, with a minimum of 5 drugs including an injectable drug 
during the first six months of intensive phase of treatment (Kanamycin, Moxifloxacin (MFX), 
Ethionamide (ETO), Terizidone (TDR), Ethambutol (EMB) and Pyrazinamide (PZA)). The 
intensive phase was followed by 12 months of four drugs MFX/ETO/PZA/TDR after culture 
conversion during the continuation phase.[59] Patients were started on treatment when they 
presented to the focal point clinic with a GXP result showing Rifampicin resistance. Their 
injectable drugs during intensive phase were administered daily by a nurse at primary health 
care centres closer to where they resided. Patients were followed up at 2 weeks, 4 weeks then 
every 4 weeks thereafter, to monitor clinical response, and blood tests, sputum culture/DST, 
side effects were also assessed at these visits.  
In its National Strategic Plan, SA planned to improve the DRTB treatment success rate to 
75%.[10] DRTB treatment outcomes can be improved if more resources and healthcare 
commitment is dedicated to the control of the disease. 
1.2 Problem statement: 
The DRTB clinic at CMJAH treated patients with DRTB not warranting an admission to the 
centralized unit. This population had a very high TB/HIV co-infection rate, highly mobile 
population treated in an ambulatory urban setting. HIV/TB coinfected patients with 
concomitant use of anti-TB drugs and ART were more likely to have adverse events and the 
worst treatment outcomes compared to HIV uninfected patients. [4, 33, 44] The World Health 
Organization (WHO) has reported poor DRTB treatment outcome globally in their 2017 report, 
with SA having success rates of 54% and 27% for MDR/RR-TB and XDRTB respectively. [33] 
Poor drug resistant TB treatment outcomes pose a major threat to the TB programme in the 
country. This has been a major public health concern as transmission of the resistant strains in 
the community occur if TB is not diagnosed and treated early and appropriately. The country 
aimed to improve their DRTB success rate to 75%, as stipulated in their National Strategic 
Plan. [10] Centralisation of care and institutionalisation of DRTB patients has been historically 
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been practiced in SA. Delays in initiating DR-TB treatment after diagnosis were still 
experienced due to the centralisation of DR-TB treatment and care and hence a move to 
decentralize DRTB care in SA.[12] The centralised TB hospital (STIDH) focus on treating 
DRTB cases in hospital, and the patients are referred from all over the Gauteng province for 
their treatment and management. This may increase the time it takes from the initial Rifampicin 
resistance diagnosis by Xpert® MTB/RIF to referral to the centre and to initiating anti-TB 
drugs, even when such testing has shown to decrease the time to treatment in TB patients. [16] 
Availability of beds to admit these patients at central DRTB hospitals has been a challenge in 
view of increased demand for hospitalisation for very sick patients with DRTB in SA. The 
decentralised and ambulatory care models treat all other mono-resistant, stable smear negative 
MDR-TB cases. Decentralisation and de-institutionalisation of treatment and care of DR-TB 
has shown to improve the time to TB treatment. [16] Understanding the predictors of poor DR-
TB outcomes will facilitate the actions needed to be undertaken to improve these poor 
outcomes. [10, 33] 
SA has a very high HIV prevalence, with 7.1 million people living with HIV which may have 
fuelled the TB burden.[63] Deaths due to TB in HIV co-infected patients were high in this region 
prior to Anti-Retroviral Therapy (ART) roll-out in SA compared to elsewhere, and they 
remained high even after the massive ART roll-out.[5, 14] ART coverage in TB/HIV co-infected 
patients has improved drastically and despite 88% of HIV/TB co-infected patients receiving 
ART, DRTB treatment outcomes remained poor despite the evidence that ART improve TB 
treatment outcomes with up to 86% reduction in mortality.[8, 13, 33]  
1.3 Justification of the study 
In SA DR-TB treatment outcomes have been evaluated for decentralised community DR-TB 
treatment and care models in rural and peri-urban communities. In these studies, patients were 
followed up in their communities by community nurses and/or counsellors. Treatment 
outcomes are needed in such a setting in an urban decentralised ambulatory clinic, with clinic-
based outpatient care with a highly mobile population, without the healthcare workers going 
into the community for the patient’s care and treatment. There is paucity of data reporting on 
any RR-TB outcomes in ambulatory decentralised settings other than treatment outcomes for 
MDR and XDR-TB in urban or peri-urban settings. This study evaluated outcomes of any 
Rifampicin resistant TB in an urban decentralized ambulatory care setting. SA’s target is to 
increase the DR-TB treatment success rate to 75% according to the National Strategic Plan 
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(NSP). [10] DR-TB treatment outcomes in such a setting will inform whether ambulatory care 
model improve outcomes in a very mobile population and understanding the predictors of these 
outcomes is needed to improve DR-TB treatment outcomes and further curb the spread of 
DRTB in the community.  
1.4 Research question: 
What were the DR-TB treatment outcomes in a decentralized ambulatory urban setting and the 
predictors of unsuccessful outcomes?    
1.5 Literature Review 
1.5.1. Burden of DRTB  
WHO estimated that 490 000 new cases of MDR-TB emerged globally in its 2017 TB Report. 
[33] This meant the incidence of DR/RRTB was 4.1%, with a higher incidence of 19% among 
patients previously treated for TB. WHO has defined 30 countries as having the highest burden 
and contributing hugely to the global burden of TB, and SA was among those high burden 
countries. [33] Locally in SA it was estimated that there were 19 000 incident cases of MDR/RR-
TB in 2017according to the same report. [33] 
A recent survey reported in 2017, investigating the burden of DRTB in SA between 2012 and 
2014 from the National Institute for Communicable Diseases (NICD), reported a 3% MDRTB 
burden and an even higher Rifampicin mono-resistance burden of 5%, with a higher burden 
seen among those previously treated for TB. [48] The results are aligned with those reported by 
the WHO in their 2017 TB report which estimated TB cases with MDR/RR-TB was 4% in SA. 
[33] A cross-sectional survey by Cox et al, also showed a very high burden of MDRTB in an 
urban township in South Africa. [31]  Similar burden of disease has been seen in other different 
studies done in DR-TB patients in SA. [5, 26, 31]. 
 SA experienced the largest increase in the number of MDRTB between 2011 and 2012 as 
stated by a report by WHO from a Think Tank Meeting held in SA [12], although a decline has 
been achieved during the 2017 reporting year according to WHO. [33] The high prevalence of 
HIV has fuelled the incidence of TB in this region. SA has one of the highest TB and HIV co-
infection rates. [48] Wells et al has referred to this high HIV burden causing a rise in TB 
incidence the “perfect storm”. [61] In the recent TB survey in SA, the rate of TB and HIV co-
infection was higher within the Gauteng province at 75%. [48] There was a high rate of DR-TB 
among patients staring ART in SA. [27] HIV itself has been associated with development of 
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Rifampicin mono-resistance in a case control study. [18] TB was among the top conditions 
causing death worldwide. [33] Mortality among TB patients co-infected with HIV is much 
higher than seen among those HIV uninfected TB patients. [33] Gauteng province was among 
the top of the provinces with the highest number of people infected with TB and second highest 
after Mpumalanga in the recent national DRTB survey. [2, 12, 48] 
1.5.2 Decentralization of DRTB treatment 
In SA, TB and especially DRTB remained a major public health challenge and the government 
had tried scaling up interventions and strategies that were to address this. [2, 12] Some of these 
strategies were to increase ART roll out for all patients with TB including those with DRTB 
and to decentralize the management of DRTB. Decentralization of DRTB treatment meant that 
all PHC facilities were to start providing treatment to all DRTB patients without referring them 
to a centralized facility for management.[2, 12] Decentralization was implemented in order to 
increase treatment coverage of DRTB patients and to reduce the time to initiation of DRTB 
treatment to less than 5 days after diagnosis of DRTB.[2] The SA DOH policy framework on 
managing DRTB stipulated that these patients needed to be managed closer to their homes in 
order for them to commence treatment as early as possible but also to improve adherence to 
the treatment.[2] Within this framework it was proposed that patients be treated outside of the 
traditional centralized facilities, as the incidence was rising and these facilities could not cope 
due to human resources among other reasons. 
A meta-analysis done by Williams et al, looked at 27 high TB burden countries and concluded 
that higher treatment success rates were seen in patients managed in the community compared 
to hospitalized patients. [32] Access to treatment was improved by decentralized care models. 
The study also concluded that the strategies put in place in the communities to manage lost to 
follow up patients had a positive influence on treatment success. Feasibility of treating DRTB 
patients outside the centralized hospital setting has also been shown for resource constraint 
countries.[32] Weiss et al meta-analysis has shown that outcomes in community model of care 
had a success rate of 65%.[6] This is an average above that seen globally but they found no 
significant difference in this study for treatment success.[6, 33] Community based treatment of 
DRTB patients appeared to have adequate treatment outcomes as seen in Weiss et al and 
Williams et al. [6, 32] The same results were seen even in resource constrained  settings.[4, 24, 36] 
Many studies looked at DRTB treatment outcomes from community based decentralized care 
models and lacked to investigate clinic based decentralized care models, particularly in urban 
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settings. An ambulatory care model in Indian slums in patients infected with HIV showed 
encouraging treatment outcome results. [36] This Indian study is the only one that investigated 
an ambulatory care model in DRTB patients co-infected with HIV. 
Treating DRTB patients outside centralized facilities has been seen to be feasible and it has 
contributed to reduced treatment delays seen in the TB programmes and it has improved 
survival of these patients. [4] 
1.5.3 DRTB Treatment outcomes  
WHO reported that the proportion of patients diagnosed with MDRTB or any RRTB who 
achieved successful outcomes (cured and completed) was 54%, with 16% deaths, 30% lost to 
follow-up, 9% were treatment failure in 2017. [33] The lost to follow up rate has doubled since 
2013. TB was among the top conditions causing death worldwide and caused more deaths than 
HIV by 2016. [33] TB accounted for additional deaths within the HIV co-infected population. 
[33] 
Successful treatment outcomes in a meta-analysis by Williams et al (including studies from 
nine countries with a high TB burden), comparing community and hospital care models has 
shown better outcomes for community versus hospital care (68% vs. 57%).[32] Treatment 
failures were also lower in community compared to hospital-based treatment at 7% vs. 19%, 
although the HIV co-infection prevalence was low in these studies.[32] The mortality rate of 
patients with MDR/RR-TB in SA was reported to be around 20%.[12] SA aims to improve their 
DRTB success rate to 75% by end of 2022 according to the NSP goals. Despite reported good 
drug susceptible and DR-TB outcomes elsewhere in the world, DR-TB outcomes remained 
poor in SA, with success rates of below 60% in different settings. [14, 38, 40] The country has not 
yet achieved its DRTB treatment successful outcomes target of 75%, as stipulated in the 
National Strategic Plan.[10] This is threatening the control of TB in this country currently and 
in years to come if no improvements are made. For SA, WHO reported an estimation of 
MDR/RRTB treatment success to be 54% and 27% for XDRTB in 2017. [33] The picture seen 
in SA is testament to generally poor treatment outcomes in DRTB patients compared to drug 
susceptible TB. When we look specifically at the HIV infected population, the DR-TB 
treatment outcomes in other countries with a high HIV burden were better than those seen in 
SA.[23-25] South Africa is among countries in the world with high death rates and loss to follow 
up of DRTB patients.[33] Despite reported improved drug sensitive TB outcomes, treatment 
success rates remain poor among patients with MDR-TB, especially those co-infected with 
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HIV even with a high ART coverage, as we see in a study by Umanah et al, although this 
looked only at centralized care model.[40] In SA’s community decentralised care models in the 
rural and peri-urban settings, showed better treatment DR-TB outcomes due to interventions 
that improved and supported the MDR-TB control programme.[4] In other countries a high cure 
rate was achieved, although sample size in some studies was small.[23, 25] The study by Isaakidis 
assessed treatment outcomes in an ambulatory model in an Indian slum setting in HIV co-
infected patients, and showed comparable outcomes to other SA studies.[36] Treatment default 
of patients is a challenge in managing and controlling TB. Patients are lost due to the prolonged 
duration of treatment for DR-TB, side effects of the drugs, the injectable route of drug 
administration during IP, and in SA particularly financial and transport challenges fuel the poor 
control of DR-TB. [9] MDR-TB is treatable only if patients are given appropriate therapy and 
treatment is adhered to.  
The Stop TB Partnership Global Plan estimates that 1 million cases of MDRTB need to be 
detected and started on treatment and achieve treatment success in over 75% of these cases.[11] 
There was only very few of the countries globally which were able to achieve this set treatment 
success target.[11] South Africa was still lagging behind its own target, and if appropriate 
interventions are no implemented, for example: full implementation and financial and human 
resource mobilization to support the decentralised management of MDR-TB, implement 
psychosocial support for these patients, shortening of treatment duration and limiting adverse 
events this target may not be achieved in the near future. SA plans to decentralise treatment 
and care to all primary health care facilities so that primary healthcare nurses start treating 
patients with DR-TB and initiate treatment within five days. 
1.5.4 Time to unsuccessful treatment outcomes (death and default) 
In different studies time to unsuccessful outcomes has shown to be very short, with many 
patients dying or defaulting within the first 6 months of treatment (intensive phase). [28, 37, 43] 
Median survival times for death outcome seen in a study by Isaakidis et al was the shortest at 
27 days (range of 1 to 229 days) after DRTB treatment was started.[36] Kliiman et al study done 
in Estonia examined patients with MDRTB and XDRTB had a median time to death of 5 
months,[28] whereas another study in Russia showed median time to death was just over 1 
month.[43] Survival times of patients with DRTB showed similar times compared to a study 
done in Asia by Hoa et al on drug susceptible TB. Hoa et al examined time to unsuccessful 
outcomes in three Asian countries and found that half of the deaths occurred within the first 2 
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months of initiating TB treatment in Cambodia and 11 weeks in China and Vietnam although 
this study only examined drug susceptible TB [37]  Hoa et al also examined the median time to 
default in the same study and it was 2 and 3 months in China and Cambodia/Vietnam 
respectively.[37] These findings are very pertinent as they raise a challenge that needs to be 
addressed for these patients especially within the first few months of initiating TB treatment.  
1.5.5 Predictors of unsuccessful DRTB outcomes 
Different studies have examined the predictors of poor outcomes in different settings and have 
found different demographic and clinical factors associated with poor outcomes. Among these 
factors male gender, older and younger age, previous history of TB, positive sputum smear, 
cavitatory diseases, low CD4 count and no ART initiation in HIV infected patients were some 
of the predictors of death and/or failure. [21, 28, 35] 
Male gender was found to be a predictor of poor outcomes in a meta-analysis by Johnston et 
al. [35] In the same study, other predictors of poor outcomes were alcohol abuse, low BMI, 
smear positivity at diagnosis, fluoroquinolone resistance and XDR resistance pattern. [35]  Brust 
et al showed that more baseline drug resistance and prior TB were independent risk factors for 
treatment failure.[21]   
HIV has been associated with poor treatment outcome in different studies. [14, 21, 28] HIV co-
infection with DRTB was a predictor for death and a predictor of default in a few studies. [14, 
21, 37] Deaths due to TB in HIV co-infected patients remained high in this region compared to 
elsewhere, despite the massive Anti-Retroviral Therapy (ART) roll-out.[5, 14, 41] ART coverage 
in TB HIV co-infected patients remains low, despite the evidence that ART improve TB 
treatment outcomes with up to 86% reduction in mortality.[8, 10, 13] In SA only half of TB patients 
co-infected with HIV had been initiated on ART’s in 2012.[5] For HIV co-infected individuals, 
initiating ART has shown to improve treatment outcomes in patients with MDR-TB.[13, 14] 
Initiation of ART in HIV co-infected patients during TB treatment in patients with MDR-TB 
was associated with a 86% reduction in mortality.[13] A study done in a SA centralised care 
model showed that timing of ART initiation was important in MDRTB patients, as it had an 
impact on mortality.[41] In the same study mortality was high among HIV co-infected patients 
who initiated treatment before MDRTB treatment was started, similar results shown in another 
SA study by Abdool Karim et al.[8] A study in Botswana has shown no difference in early 
MDRTB treatment outcomes, when looking at early culture conversion between HIV co-
infected and HIV uninfected patients.[42] With these finding they concluded that the outcomes 
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may be comparable in similar settings. In HIV and TB co-infected patients, low CD4 count 
<100 increased mortality in DRTB co-infected patients in a study by Mohr et al. [62]  
Previous history of TB treatment was found to be another independent predictor of poor 
outcomes. Urban residence has been shown to predict poor treatment outcomes for XDRTB 
patients in particular. [28] Kliiman et al also showed that having high grade smear positivity of 
DRTB was a risk factor for poor outcomes [28]  Low baseline weight,  <60kg and <45kg and a 
low body mass index (BMI) were also associated with higher hazards of death and/or treatment 
failure. [14, 24, 41] Integrated TB and HIV care services have shown to improve treatment 
outcomes. [8, 9, 19]  
In a study done in SA, low haematocrit was a predictor of death, although this study was done 
before the SA national ART roll-out. [14] Severe anaemia was also a predictor of failure in a 
study by Umanah et al, which also associated co-morbid conditions like Diabetes mellitus 
(DM) with treatment failure. [41] Diabetes as a co-morbid condition was also associated with 
poor treatment outcomes in a study by Periasamy et al, although the sample size was very 
small. [34] In the same study smoking and patients diagnosed with pre-XDRTB were also 
predictors of poor outcomes. [34] Cavities on CXR at baseline were independent risk predictors 
of mortality in patients with HIV co-infection rate in SA centralized model. [41] 
Health system factors have also been associated with poor outcomes. Some of these factors are 
cross-border management of patients in terms of the continuum of care and reporting of the 
treatment outcomes, financial support for these patients, and health care providers’ ability to 
support and treat these patients holistically. [9, 17] Addressing these factors will improve 
treatment outcomes. A meta-analysis by Weiss failed to show any factors associated with 
treatment success. [6] 
1.5.6 Summary of literature review findings:  
DR-TB treatment outcomes are generally poor globally. There are good DR-TB outcomes from 
other countries but SA has shown outcomes that are below those of many countries, this may 
be due to lower HIV prevalence in these countries. SA has failed to achieve its target for 
successful DRTB treatment outcome of 75%. DR-TB decentralised care and treatment models 
have been widely documented and have shown improved outcomes compared to the 
centralised/hospitalized care models. The decentralized models of care have not been widely 
implemented in urban settings in SA wherein the population is highly mobile as seen in the 
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City of Johannesburg. MDR and XDR-TB treatment outcomes have been studied extensively 
but there is paucity of literature evaluating outcomes for any form of RR-TB other than MDR-
TB and XDR-TB. Ambulatory care models in urban settings have not been broadly evaluated. 
There was paucity of literature assessing time to unsuccessful DRTB outcomes. Time to 
unsuccessful DRTB outcomes was evaluated in only two studies, Isaakidis et al and Kliiman 
et al which reported very short survival times, with the median time to death of 27 days and 5 
months respectively. [36, 43] Other studies evaluated survival times in patients with drug 
susceptible TB and the results showed similar findings of median times of 2 and 3 months. [37, 
43] These findings are important as measures to improve survival of these patients need to be 
implemented especially during the IP of treatment.  
Several predictors of poor outcomes have been reported in many studies and these included 
some demographic characteristics for example being male gender, advanced or younger age 
and smoking history. [21, 28, 29]  Clinical characteristics associated with poor outcomes were 
higher baseline resistance, smear positivity, previous TB treatment, baseline cavitatory disease, 
HIV co-infection with low CD4 count and not initiated on ART. Co-morbid conditions like 
DM were also independent predictors of unsuccessful outcomes. Low body weight <45kg and 
<60kg and BMI were some of the predictors found in different studies. 
1.6 Study Aims and Objectives 
1.6.1 Aim of the study 
To evaluate DR-TB treatment outcomes and to determine the predictors of these outcomes. 
1.6.2 Study Objectives 
1. To describe all RR-TB treatment outcomes: treatment success (cured and completed), 
unsuccessful treatment outcomes (died, treatment failure and lost to follow-up) and 
transfer out. 
2. Assess any differences in outcomes between HIV positive and negative patients 
3. To describe time to unsuccessful treatment outcomes (death and defaulted). 
4. To assess the predictors of death, default and overall unsuccessful treatment outcomes. 
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2. CHAPTER 2: METHODOLOGY 
 
2.1 Introduction 
This chapter reviews the study design, study population and setting and selection of the study 
site, sampling and selection of the patient population, measurements and data sources. Also 
discussed in this chapter are key definitions, data management and analysis, and ethical 
considerations. 
2.2 Study design: 
A retrospective study design using secondary data of patients’ records was used to analyse 
routinely collected data. The data were extracted from the clinic’s database, at the DR-TB 
outpatient clinic at CMJAH covering the period from 1stJanuary 2010 to 31stJanuary 2014.  
2.3 Study setting: 
CMJAH is one of the two tertiary (academic) hospitals located in the inner City of 
Johannesburg (COJ). The outpatient TB clinic at CMJAH is a specialist clinic which serves as 
a referral site for complicated TB cases and any DR-TB patients from feeder primary healthcare 
centres. It is an urban decentralised specialist DR-TB clinic. The clinic started operating in 
2010 as a decentralised ambulatory DR-TB site which serves as a referral centre for PHC in 
the inner city of Johannesburg. The clinic enrolled any patient with DRTB except those who 
came with XDRTB and smear positive MDRTB 
2.4 Study population: 
The study population consisted of patients diagnosed with any RR-TB and enrolled into care 
at the CMJAH TB focal point between 1st January 2010 and 31st January 2014.  
2.5 Study sample: 
A total of 335 patients with any form of Rifampicin resistant TB diagnosed during the period 
January 2010 to January 2014 found in the database were included in the study. The following 
criteria was used to ensure appropriate selection of patients into the study.  
2.5.1 Inclusion criteria: 
Patients included in the study were:  
• 18 years and above 
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• Laboratory diagnosis of any Rifampicin resistant TB  
• Started treatment at the CMJAH DRTB outpatient clinic. 
 
2.5.2 Exclusion criteria:  
• TB cases with drug susceptible (sensitive) TB 
• Non-tuberculous mycobacteria (NTM) or otherwise known as mycobacteria other than 
TB (MOTT)  
• Other mono-resistant TB other than Rifampicin 
• Patients under the age of 18 years 
• Patients who were enrolled outside the study period. 
2.6 Data source and measurement: 
2.6.1 Data collection and procedures: 
As part of the clinic’s routine care, data in the clinic were collected routinely from clinical 
records of patients and data entered in the TB Focal Point Access database. The data clerks 
routinely transferred data from the clinical records into the MS Access database as part of 
normal day to day record keeping and management. Data were updated at every patient visit. 
Patients’ demographic information were collected by the clerks whereas the clinicians collected 
clinical history as part of routine care.  
As part of routine care, HIV counselling and testing was offered to all patients where status is 
unknown or negative previously. HIV rapid testing were done and if positive a laboratory HIV 
Enzyme Linked Immuno-sorbent Assay (ELISA) confirmation done. CD4 counts were done 
in all HIV positive patients. No baseline VL were done, as recommended by the SA HIV 
management guidelines. Patients not already on ART were initiated on ART within 2 to 8 
weeks of starting anti-TB drugs, unless they refused treatment. Decision to initiate ART was 
based on CD4 count below 350 cells/mm3. This was later followed by a guideline change in 
management for all TB patients to start ART irrespective of CD4 count at a later stage. Patients 
received their ARTs and anti-TB drugs at the same clinic for the duration of TB treatment for 
better management of both diseases. 
Patients diagnosed at the feeder clinics with any form of DRTB on sputum XPert® MTB/RIF 
were referred to CMJAH TB clinic for further management and initiation of therapy. On 
enrolment at the CMJAH TB clinic, patients were registered, examined and sputum collected 
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for confirmation of type of resistance. Confirmation of the results were done using Line Probe 
Assay (LPA) and culture and drug sensitivity testing (DST) for first and second line TB drugs. 
These tests were done by the National Health Laboratory Services (NHLS). The culture and 
DST done by NHLS used liquid media such as BACTEC Mycobacterial Growth Indicator Tube 
(MGIT) 960 and Becton Dickinson.  
Drug Resistant TB treatment regimen used:  
Most patients in the clinic were initiated on standardized 5 drug combination anti-TB treatment 
and were treated for a maximum of 18 to 24 months. Some patients initiated were initiated on 
individualized regimes due to varying reasons, for example prior to 2012 there were no 
standardized DRTB treatment guidelines. Individualized treatment regimens were also given 
in patients who had or developed adverse drug reactions and those with co-morbid conditions 
like renal failure or psychosis. Patients on a standardized regimen, were initiated on a 
combination of Kanamycin (KM) or Amikacin (AM) injectable, Terizidone (TDZ), 
Moxifloxacin (MFX), Ethionamide (ETO) and Pyrazinamide (PZA) during the intensive phase 
of therapy which was at least 6 months. Injectable treatment was stopped after the IP of therapy 
when TB cultures have been negative. Treatment was taken daily except the injectable which 
was taken for 5 days per week during the intensive phase. Injectable treatment was 
administered by a nurse at their local PHC facility near where they resided, this also facilitated 
DOTS for these patients by their local PHC nurses. Patients who were too ill to warrant hospital 
admission, any smear positive DRTB were referred to the centralized facility at STDIH for 
admission or further management. 
Clinicians continued to monitor patients’ monthly for clinical progress, adverse events, sputum 
smear and cultures and DST, CXR and any other new medical conditions until 1 year after 
completion of therapy. The clinic had a dedicated sputum collection nurse ensured that all 
patients’ sputum samples were collected at all their clinic visits. 
The following data were collected as part of routine care at the facility: 
Demographic data: Included gender, age, employment history, referral facility and 
citizenship.  
Clinical data: Included baseline weight, site of TB, ART’s, RR-TB diagnosis, date of starting 
TB treatment, treatment outcomes (cure, completed, default, died, failed and transferred-out) 
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and date of outcome and co-morbid conditions (Diabetes, liver disease, renal failure, Epilepsy). 
Baseline weight was done for all patients.  
Laboratory data: Included blood and sputum test results. 
Blood tests: HIV status, CD4 count, viral load, urea, electrolytes and creatinine, thyroid 
function tests, haemoglobin and liver function tests.   
Sputum tests: Included Xpert® MTB/RIF, smear (AFB), line probe assay, microscopy, cultures 
and DST.  
As part of this study, the hospital’s Resistant TB focal point database was searched for all the 
patients who were enrolled from January 2010 to January 2014 with any RR-TB diagnosis. 
data were extracted for this analysis in August 2015. For this study only data of interest to the 
analysis were extracted from the database. 
Below are data variables that were extracted and used in the analysis for this study: 
2.6.2 Treatment outcome variables: 
The outcomes variables assessed were successful, unsuccessful and transfer out. Successful 
outcomes included cured and completed treatment. Unsuccessful outcomes included death, 
treatment failure and lost to follow-up. WHO DRTB treatment outcome definitions were used 
together with the South African Department of Health Drug-resistant TB Policy Guidelines 
2013. 
Outcome variables and definitions: 
1. Cured - treatment completed without evidence of failure and three or more 
consecutive cultures taken at least 30 days apart are negative after the intensive phase. 
If only one positive culture is reported during that time, and there is no concomitant 
clinical evidence of deterioration, a patient will still be considered cured, provided 
that this positive culture is followed by a minimum of three consecutive negative 
cultures taken at least 30 days apart. 
2. Completed treatment - treatment completed without evidence of failure but no record 
that three or more consecutive cultures taken at least 30 days apart were negative after 
the intensive phase. 
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3. Treatment success –the sum of those who were cured plus those who completed 
treatment. 
4. Default – a patient whose treatment was interrupted for two consecutive months or 
more.  
5. Transfer out was defined as all whose care was transferred to other healthcare centres 
treating DR-TB. This did not include those patients transferred immediately to STIDH. 
6. Treatment failure - treatment terminated or need for permanent regimen change of at 
least two anti-TB drugs due to: lack of conversion by the end of the intensive phase; or 
bacteriological reversion in the continuation phase after conversion to negative; or 
evidence of additional acquired resistance to fluoroquinolones or second line injectable 
drugs and due to adverse drug reactions. 
7. Died (All-cause mortality) – a patient who died for any reason during the course of 
treatment. 
8. Unsuccessful outcome – a sum of died, default and failures. 
9. Still on treatment – patients who at the end of this study period were still taking their 
TB medications. 
2.6.3 Exposure variables: 
1. Socio-demographic variables:  
• Age: patients’ age in years at time of starting TB of treatment 
• Gender: gender of patient (male or female) 
• Nationality: SA or non-SA 
• Employment: employed or unemployed at time of starting TB treatment 
• Education level: patients’ education level (education or no education) 
• Referral site: health facility where patient was referred from. 
2. Clinical and laboratory variables:  
• Weight: body weight at time of starting treatment 
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• TB diagnosis: laboratory diagnosis/type of TB resistant strain (MDR, XDR, RMR, 
XDR, RR not confirmed by DST/LPA) 
• Site of TB: pulmonary or extra-pulmonary 
• HIV status: HIV diagnosis of patient (negative or positive) 
• CD4 count:  CD4 at baseline (CD4 <200; 200-350; 350-500 and >500) 
• ART: patient on ART or not on ART at time of outcome  
• History of previous TB: New, Retreatment after 1st line default/failure and 
Retreatment after 2nd line default/failure 
• Comorbid conditions: Diabetes Mellitus, Epilepsy, Liver disease, Renal 
insufficiency 
2.7 Data Management 
Data were entered in the clinic on a MicroSoft Access database.  For any missing data, the 
patient records were used to correct and update the database. Data were exported into STATA 
version 12.0 for data cleaning and analysis. Data cleaning was done by excluding patients not 
eligible for the study according to the exclusion criteria, and removing unwanted variables that 
were not important for this study objectives. Missing data were assessed for all variables 
important for the analysis.  
A total of 760 patients were ever enrolled to CMJAH TB clinic at the time of data extraction 
by August 2015. Patients who were enrolled between January 2010 and January 2014 were 605 
(80% of ever enrolled to clinic). Of these 605 patients; 375 (61%) had any Rifampicin drug 
resistant TB, 36 (6%) had INH mono-resistance, 50 (8%) had MOTTs, 174 (28%) had drug 
sensitive TB and 5 (0.8%) had no information on TB diagnosis. These patients with INH mono-
resistance, sensitive TB, MOTTs and those without information on TB diagnosis were 
excluded from the study (see Figure 1). Duplicates and those aged below 18 years (5 
observations) were excluded from analysis. All 335 patients were analysed during the 
descriptive analysis, but only 321 patients were analysed for the outcomes measure, due to 14 
of them being on treatment at time of data extraction. Outcome measures of 5 patients were 
recorded under the wrong variable and were changed, which included 3 deaths and 2 defaulted 
patients’ outcome measures recorded under outcome variable “Other”. 
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Fig 1: Flow chart illustrating participants analysed for Drug Resistant TB outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age, weight and CD4 count were analysed as both continuous and/or categorical variables. 
Age was categorized into 2 groups <40 years and >40 years; weight (<50kg, 50-59kg, 60-70kg 
and >70kg); and CD4 count grouped (<200 cell/mm3, 200-350 cell/mm3, 350-500 cell/mm3and 
>500 cell/mm3). This was done to avoid confounding which may be seen when these data are 
modelled as continuous variables. One patient was recorded to be on ART yet HIV negative, 
so CD4 count was not analysed. A total of 5 patients had their weight below 29kg which were 
highly likely to be wrong for an adult patient and therefore were assumed to be missing and 
not analysed (5 observations). Normality of continuous data was assessed using histograms, 
quantile plots, and skewness and kurtosis were evaluated. Shapiro Wilk test was also used to 
assess for normality of continuous variable. New variables which were necessary for analysis 
were generated from existing variables in the dataset. The new DRTB duration variable was 
generated. Person times were calculated from the date of DRTB treatment start date and date 
of outcome. For time duration to final outcome, dates which created a negative time were 
excluded from the analysis. Categorical variables with sparse observations were merged, for 
example nationality into SA and non-SA. Education was also merged into Education and No 
Education. For retreatment patient category, data were merged into 2 groups, namely 
retreatment after regimen 1(default/failure with regimen 1) and retreatment after regimen 2 
(default/failure with regimen 2). For diagnosis DRTB categories, Poly-resistant TB and 
760 patients in database at 
data extraction 
36 - INH mono-resistant TB 
174 - Drug Sensitive TB 
50 - MOTT’s  
05 - No information on TB 
diagnosis 
 
340 patients with any 
Rifampicin resistant TB 
 2 - Duplicates 
 3 - Age <18 years 
 
 
14 Still on treatment 
 
605 patients enrolled from 
Jan 2010 to Jan 2014 
155 enrolled after Jan 2014 
321 patients analysed for 
the outcomes 
 
335 patients analysed for 
descriptive analysis 
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XDRTB categories were merged with MDRTB category due to very small number of patients 
(less than 5) within these two categories.  
Outcome measures were stratified by HIV status. New outcome variables were generated for 
outcome, namely successful and unsuccessful.  
2.8 Data analysis: 
2.8.1 Descriptive and Inferential analysis  
Proportions and frequencies were used to describe all categorical baseline and clinical variables 
in the data. Distribution tables were used to demonstrate demographic and clinical data. 
Continuous variables were described by their mean and standard deviation if they were 
normally distributed; and by a median and interquartile ranges if the data were skewed. 
Normally distributed continuous data were displayed using histograms. Both demographic and 
clinical data were described and compared between the different outcome measures. Outcomes 
measures were analysed separately then categorized into successful (the sum of cured and 
completed treatment), unsuccessful (treatment failure, died, lost to follow up) and transfer out. 
Differences in the outcomes were compared by HIV status. Equality of proportions between 
HIV negative and HIV positive patients was analysed to show the effect of HIV on treatment 
outcomes. Kaplan-Meier survival estimates were used to estimate survival times. Median and 
interquartile ranges were used to describe survival times. 
2.8.2 Univariable and Multivariable analysis 
The predictors were only determined for unsuccessful outcomes. Univariate Cox regression 
models were used to estimate crude hazards ratios of the predictors associated with both death 
and default separately, and then combined for unsuccessful outcomes. Multivariate Cox 
regression models were used to estimate the adjusted hazards ratios. All covariates with p-value 
less than 0.1 from the univariate models were selected into the multivariate models. For the 
Cox regression, the Efron’s approximation method for ties which is more accurate than the 
Breslow’s method (being the default used in Stata survival analysis) was used. Priori 
biologically plausible covariates considered important were also included in the multivariable 
regression analyses.  
2.8.3 Model diagnostics 
Goodness of fit of the final model were tested (Appendix 4). 
32 
 
2.9 Ethical Considerations 
Ethics approval to conduct this study was sought from the Wits University Human Research 
Ethics Committee (HREC), see attached Appendix 6. Permission to use the hospital’s database 
was also sought from the CEO of CMJAH, also attached in Appendix 5. Identifying 
information from the database was removed during data extraction, and the use of unique 
identifiers employed.  
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3. CHAPTER 3: RESULTS 
3.1 Introduction:  
In this chapter the results are presented according to the study objectives and the analysis plan. 
This includes: demographic, clinical characteristics, time to treatment, successful outcomes 
and unsuccessful treatment outcomes, and predictors of poor treatment outcomes are presented. 
3.2 Baseline demographic characteristics of participants 
Table 1.1 below shows a description of demographic characteristics of the patients with any 
RR-TB. Among the 335 patients diagnosed with any RRTB, 52.5% of them were female. 
Median age in the study was 34 years. The study observed that DRTB was diagnosed more in 
patients older than 40 years of age. Only 15.5% of the patients had a history of having attained 
some level of education. Unemployment rate was 22.5% among those where history of 
employment was known. Majority of the patients 97.3% were SA citizens. 86% of the patients 
were referred from PHC facilities. 
Table 1.1: Baseline Demographic Characteristics of all RR-TB Patients at CMJAH 
from January 2010 to January 2014. 
Characteristics Level N (%)                         (N=335)         
Age (years) 
 
*34 (18 – 81) 
<40 
>=40 
 
229 (68) 
106 (32) 
Gender 
 
Male 
Female  
159 (47.5) 
176 (52.5) 
Nationality 
 
South African  
Non-SA 
326 (97.3) 
9 (2.7) 
Employment 
 
Employed 
Unemployed 
Unknown  
Missing  
51 (15.2) 
82 (24.5) 
196 (58.5) 
6 (1.8) 
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Education 
   
Education 
No Education 
Missing 
52 (15.5) 
74(22.1) 
209 (62.4) 
Referring facility Primary Healthcare 
Private facility 
CMJAH wards/speciality OPD 
Other hospital 
Missing 
288 (86.0) 
3 (0.9) 
25 (7.5) 
9 (2.7) 
2 (0.6) 
                            # = Number          %= Percentage                                       * = Median (Inter-quartile range) 
 
 
3.3 Baseline clinical characteristics  
Table 1.2 below shows baseline clinical characteristics of the patients in this study. The study 
observed that the number of patients being diagnosed for the first time with DRTB found in 
this study was high, with 71.9% of patients having no prior history of TB. Approximately only 
a third of the patients in this study had a previous TB treatment prior to being diagnosed with 
DRTB, 79 (23.6%) were retreatment after failing regimen 1 and 15 (4.5%) were TB retreatment 
or failing regimen 2. Majority of the patients in this study were diagnosed with confirmed 
Rifampicin mono-resistant TB (34%) and MDRTB at 26.9%. The prevalence of poly-drug 
resistance and XDRTB was 1.5%. The remaining 37.6% of patients were Rifampicin resistant 
diagnosed on GeneXpert only, without any confirmation by either culture or LPA. We observed 
that 96.9% of the patients in this study presented with pulmonary disease. The baseline smear 
positivity rate in the study was 58.5%. GeneXpert testing of sputum identified 20 more patients 
(6% more) with DRTB than sputum smear test alone. Half of the patients presented with 
symptom of a cough, night sweats in 127 (38%) patients, chest pains in 95 (28.4%), weight 
loss in 90 (27%) and appetite loss in 54 (16.2%).  
Of the 335 patients, all except 1 had known HIV status (99.7%).  The clinic had a very high 
uptake of HIV counselling and testing. There was a very high HIV/TB co-infection rate of 
82.9%. Among the 277 HIV co-infected patients, the ART coverage was 79.5%. Median CD4 
count was 142 cells/mm3 (IQR: 3 - 835). Of the 277 HIV infected patients baseline VL results 
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were recorded for only 27 (9.7%) patients, with only 4 of these virally suppressed. Only 42 
(15.3%) HIV co-infected patients were receiving Co-trimoxazole prophylaxis. 
Recording of CXR findings was low. CXR findings were recorded in only 113 (33.7%) of the 
patients and found to be abnormal in 24 (26.2%) of these patients. These CXR findings showed 
14 (13.1%) bilateral infiltrations, 5 (1.5%) cavitatory disease, 2 (0.6%) patients had pleural 
effusion and 5 (1.5%) had a combination of cavities, infiltrations and hilar adenopathy. Of the 
10 extrapulmonary TB patients, ultrasound showed 3 abdominal TB and 4 cardiac TB. 
The presence of co-morbidities was minimal (5.4%) in the study, 6 (1.8%) patients had 
Diabetes Mellitus, 5 (1.5%) had Epilepsy, 4 (1.2%) had Hepatitis (cause not specified), 2 
(0.6%) had renal failure, 1(0.3%) had a psychiatric condition not specified. There were 3 
pregnant women among this cohort.  
Table 1.2: Baseline Clinical Characteristics of DR-TB Patients at CMJAH from 
January 2010 to January 2014. 
Factors Level         N=335 (%) 
DRTB Diagnosis   
MDRTB 
 
Rifampicin-mono resistant 
(LPA and/or DST) 
 
Rifampicin-resistance on 
GXP (no confirmation done) 
 
Poly-resistant TB 
 
XDR-TB 
 
 
90 (26.9) 
 
114 (34.0) 
 
 
126 (37.6) 
 
 
4 (1.2) 
 
1 (0.3) 
Baseline sputum 
Smear  
 
 
Positive  
Negative  
 
 
196 (58.5) 
139 (41.5) 
Baseline sputum  
GeneXP 
 
 
Positive 
Negative 
 
 
216 (64.5) 
119 (35.5) 
Presenting symptoms:  
Chronic cough 
Yes 
No 
Night sweats 
Yes 
 
 
167 (49.9) 
168 (50.1) 
 
127 (38) 
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No 
Missing 
 
Chest pains 
Yes 
No 
 
Weight loss 
Yes 
No 
Missing  
 
Loss of appetite 
Yes 
No 
Missing 
 
Dyspnoea  
Yes 
No 
 
Fever/rigors  
Yes 
No 
Missing 
 
Haemoptysis 
Yes 
No 
 
Lymphadenitis  
Yes 
No 
Missing 
 
207 (61.8)  
1 (0.2) 
 
 
43 (13) 
292 (87) 
 
 
90 (27) 
243 (72.5) 
2 (0.5) 
 
 
54 (16.2) 
279 (83.2) 
2 (0.6) 
 
 
21 (6) 
314 (94) 
 
 
29 (9) 
301 (90) 
5 (1) 
 
 
7 (2) 
328 (98) 
 
 
2 (1) 
331 (98 
2 (1) 
History of TB  
New 
 
Retreatment after/failing 
Reg1 
 
Retreatment after/failing 
Reg2 
 
Unknown 
 
 
240 (71.9) 
 
79 (23.6) 
 
 
15 (4.5) 
 
 
1 (0.3) 
HIV status 
 
 
Positive 
Negative 
Missing  
 
277 (82.7) 
57 (17.0) 
1 (0.3) 
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HIV+ 
CD4 cell count 
 
Category: 
 
  *142 (23 - 388) 
 
<200 
200 – 350 
350 – 500 
>500 
Missing  
                       n=277 
 
 
140 (50.5) 
42 (15.2) 
26 (9.4) 
9 (3.2) 
60 (2.2) 
 
HIV+ on ART  
Yes 
No  
 
n=277 
220 (79.5) 
57 (20.5) 
HIV+ 
 
Cotrimoxazole prophylaxis   
 
 
Yes 
No 
Missing  
 
n=277 
 
4 (1.4) 
233 (84.1) 
34 (12.5) 
Site of TB  
PTB 
EPTB 
 
325 (96.9) 
10 (3.1) 
 
Weight (kg)   *54.3 (31.2 – 92.4) 
<50kg 
50-59kg 
60-70kg 
>70kg 
 
 
103 (34.0) 
116 (38.3) 
58 (19.1) 
26 (8.6) 
CXR 
 
 
Infiltrations 
Yes 
No 
 
Cavitations 
Yes  
No  
 
Pleural effusion 
Yes 
No  
 
 
 
14 (4.2) 
321 (95.8) 
 
 
8 (2.4) 
327 (97.6) 
 
 
2 (0.6) 
333 (99.4) 
Co-morbid conditions  Diabetes Mellitus 
Yes                                   
No                  
Missing            
 
Epilepsy 
Yes 
 
6 (0.8) 
333 (99.0) 
1 (0.2) 
 
 
5 (1.4) 
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No 
Missing  
 
Renal insufficiency 
Yes                   
No                   
Missing             
 
Hepatitis  
Yes      
No           
Missing                                     
329 (98.3) 
1 (0.3) 
 
 
2 (0.6) 
331 (98.8) 
2 (0.6) 
 
 
4 (1.2) 
330 (98.5) 
1 (0.3) 
 
                                                   # = Number          %= Percentage                     *=Median (Interquartile range) 
 
3.4 Description of DRTB treatment outcomes 
Overall, 64 (19.9%) patients had successful outcomes: 17 (5.1%) were cured and 47 (14%) 
completed treatment. Of the 122 (36.4%) patients with unsuccessful treatment outcomes, 30 
(9%) had died, and we observed a high defaulter rate of 27.5% (92 patients). The remaining 
135(40.3%) patients were transferred out. Patients who were still on treatment were 14 (4.2%). 
There were no treatment failures in this cohort.  
3.5 Time to unsuccessful outcomes 
Table 2.1 shows a summary of survival time to default and death (unsuccessful) outcomes. 
The study showed that defaulting happened early after initiation of treatment. The median 
time to default was 3 months (IQR: 1.4-8.5) with a defaulter rate of 0.2 per month. Deaths 
also occurred early after treatment initiation; results showed that among those who died, the 
median time of survival after starting treatment was 4.6 months (IQR: 0.9-13.8) with an 
incidence rate of 0.1 death per month. The overall median time to unsuccessful outcome 
(death and defaulters combined) was 3.2 months (IQR: 1.4-9.2). See Figures 2 and 3 below. 
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Table 2.1: Summary measures of time to unsuccessful outcomes  
    
 Survival time in months 
Unsuccessful outcome Time at risk Incidence rate  N 25% 50% 75% 
Defaulted 568.6 0.16 92 1.4 3 8.5 
Died 188.3 0.14 30 0.9 4.6 13.8 
Total 756.8 0.15 122 1.4 3.2 9.2 
 
 
Figure 2: Probability of survival of patients with unsuccessful treatment outcomes 
(death and default) treatment outcome stratified by DRTB diagnosis among DRTB 
patients at CMJAH 2010-2014
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Figure 3: Probability of survival of patients with unsuccessful (death and default) 
treatment outcome stratified by DRTB diagnosis among DRTB patients at CMJAH 
2010-2014
 
 
3.6 Treatment outcomes by HIV status: 
Table 2.2 below shows the difference in proportions between HIV infected and HIV negative 
patients in the study. There was a statistically significant difference (p=0.002) between the 
proportion of HIV positive and HIV negative patients who were Transferred out. More HIV 
co-infected patients 101 (75%) were transferred out compared to 34 (25%) HIV negative 
patients. A high proportion of HIV positive patients died (27 (90%)) compared to HIV negative 
patients (3 (10%)), although this was not statistically significant (p=0.26). There was only one 
patient with an unknown HIV status. There was no significant difference in proportions 
between HIV co-infected and HIV negative patients for successful and unsuccessful outcome.  
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Table 2.2: Comparison of DR-TB treatment outcomes by HIV status. 
 
DR-TB Treatment Outcomes 
HIV status N (%)   
Positive Negative  
P-value N=264(82.50) N=56(17.50) 
Successful Completed 41 (87.23) 6 (12.77) 0.3551 
Cured 16 (94.12) 1 (5.88) 0.1951 
Unsuccessful Defaulted 79 (86.81) 12 (13.19) 0.2005 
 Died 27 (90.0) 3 (10.0) 0.2561 
                         Transferred out 101 (74.81) 34 (25.19) 0.0020 
 
Figure 4: Probability of survival of DRTB patients by HIV status at CMJAH 2010-2014.  
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3.7 Predictors of death: 
3.7.1 Univariable Cox regression model: 
Patients diagnosed with Rifampicin resistant TB only with GXP (without confirmation by 
culture/LPA) had six times the hazard of death compared to those diagnosed with 
MDR/XDR/Poly-TB (HR=6.3; 95% CI:0.8-47.8; p=0.07) but this difference did not reach 
statistical significance. Very wide CI are noted and this may be attributed to the small sample 
size that could not show any significant difference. See Table 3.1.  
3.7.2 Multivariable Cox regression model:  
Table 3.1 below shows predictors of death. There were no statistically significant predictors of 
death and this result may be due to small sample in this study to show significant difference. 
Patients diagnosed with Rifampicin resistant TB by GXP only had six times the hazards of 
death compared to those diagnosed with MDR/XDR/Poly-TB (aHR=6.4; 95% CI:0.8-48.4; 
p=0.07) although statistical significance was not reached. A wide confidence interval is noted 
and this may be as a result of the small sample size. 
Table 3.1:  Predictors of death among patients with any RRTB at CMJAH between Jan 
2010 to Jan 2014 
 
Variables 
Unadjusted Cox regression 
analysis 
Adjusted Cox regression 
analysis 
Hazard 
Ratio 
P-value 
95% 
Confidence 
Interval 
Hazard 
Ratio 
P-
value 
95% 
Confidence 
Interval 
Gender Female Ref 
       
Male 1.053 0.894 0.494 2.242 
    
Age 
category 
<40 years Ref       
 
      
>=40 years 1.293 0.513 0.598 2.793 
    
DR-TB 
Diagnosis 
MDR/XDR/Poly-
resistant TB 
Ref 
   
Ref 
   
RIF mono-resistant 
TB 
2.97 0.306 0.369 23.917 2.965 0.307 0.369 23.851 
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RIF resistant by GXP 6.276 0.076 0.825 47.765 6.359 0.074 0.836 48.365 
 
3.8 Predictors of treatment default: 
Statistically significant predictors of default (negative predictors) seen in this study were: HIV 
infected not initiated on ART, baseline weight loss, Rifampicin mono-resistant TB diagnosis 
and Rifampicin mono-resistant TB diagnosis by GXP only. 
3.8.1 Univariable Cox regression model:  
Patients diagnosed with Rifampicin mono-resistance and those with Rifampicin resistance on 
GXP (unconfirmed) had statistically higher hazards of defaulting (HR=15.5; 95% CI 2.1-113; 
p=0.01) and (HR=18.2; 95% CI: 2.5-132; p=0.001) respectively, compared to those diagnosed 
with MDR/XDR/Poly-TB. The sample of patients diagnosed with MDR/XDTB was small and 
a possible reason for very wide CI’s noted. Patients with baseline weight loss had twice the 
hazards of default than those without weight loss (HR=1.7; 95% CI: 1.1-2.7; p=0.03) and this 
was statistically significant (see Table 3.2). Among the HIV co-infected subgroup (Table 3.4), 
being on ART had 70% less hazards of default compared to not being on ART with HR=0.3; 
95% CI: 0.19-0.6; p=0.001. HIV co-infected patients aged >40 years had 40% less hazards of 
default compared to those aged <40years but this did not reach statistical significance (HR=0.6; 
95% CI 0.4 – 1.0; p=0.06). Being a non-SA citizen had two times higher hazards of default 
than being a SA citizens, but also did not reach statistical significance (HR=2.2; 95% CI: 0.6-
6.8; p=0.19). (See Table 3.2 below). 
3.8.2 Multivariable Cox regression model:  
Patients with confirmed Rifampicin mono-resistance had fifteen times the hazards of default 
compared to those with MDR/XDR/poly-resistant TB (aHR=15.9; 95% CI:2.1-116; p=0.006) 
adjusting for weight loss. The hazards of default for those diagnosed with Rifampicin resistance 
by GXP only were seventeen times more than those diagnosed with MDR/XDR/poly-resistant 
TB (aHR=17.2; 95% CI 2.4-125; p=0.01), adjusting for weight loss. This finding may be due 
to patients who were having other resistance patterns being treated as if MDRTB and not 
getting adequate or appropriate therapy, that led to patients’ not getting better and defaulted. 
Compared to patients with no baseline weight loss, those with baseline weight loss had 1.6 
higher hazards of default (aHR=1.6; 95% CI 0.9-2.5; p=0.057), although this was not 
statistically significant when adjusted for DRTB diagnosis.  See Table 3.2 below. 
44 
 
For the subgroup of patients with HIV co-infection (see Table 3.4 below), ART initiation 
decreased the hazards of defaulting by 87% (HR=0.13; 95% CI: 0.05-0.28; p=0.0001) when 
adjusted for TB Resistance diagnosis. ART initiation in co-infected patients was seen to be 
protective factor against default in this cohort of RRTB patients. Those diagnosed with 
Rifampicin monoresistance and those with Rifampicin resistance diagnosed only by GXPert 
had 10.8 and 10.5 times higher hazards of death compared to those diagnosed MDR/XDR/Poly-
resistance TB, respectively when adjusted for ART initiation. These results are unexpected and 
may be that patients only diagnosed by GXPert without any confirmation by LPA/culture may 
have either MDR/XDRTB that was missed as a result of not confirming the diagnosis 
appropriately. Among the HIV co-infected patients, the positive predictor of default was being 
initiated on ART initiation, and negative predictors were Rifampicin monoresistance and 
Rifampicin resistance diagnosed only by GXP. 
Table 3.2:  Predictors of default among patients with any RRTB at CMJAH between 
Jan 2010 to Jan 2014. 
Variables 
Unadjusted 
Hazard 
Ratio 
P-
value 
95% 
Confidence 
Interval 
Adjusted 
Hazard 
Ratio 
P-
value 
95% 
Confidence 
Interval 
Gender Female Ref 
       
Male 0.711 0.11 0.467 1.081 
    
Age 
category 
<40 years Ref 
       
>=40 years 0.640 0.067 0.398 1.031 
    
Diagnosis 
DR-TB 
MDR/XDR/Poly-
resistant TB 
Ref 
       
RIF mono-resistant 
TB 
15.53 0.01 2.128 113.289 15.95 0.006 2.183 116.513 
RIF resistant by GXP 18.19 0.00 2.501 132.288 17.21 0.01 2.364 125.268 
No Ref 
   
Ref 
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Weight 
loss 
Yes 1.698 0.026 1.1 2.706 1.580 0.057 0.986 2.532 
 
3.9 Predictors for unsuccessful outcomes (default and death combined): 
Predictors of unsuccessful outcomes were confirmed Rifampicin mono-resistance diagnosis, 
Rifampicin resistance by GXP diagnosis. See Table 3.3 below. 
3.9.1 Univariable Cox regression model: 
Not initiated on ART had 3 times higher hazards of unsuccessful outcomes in HIV positive 
patients (HR=2.6; 95% CI: 1.6-4.4; p=0.000). For every unit increase of weight, there was 2% 
less hazards for unsuccessful outcomes (HR=0.98; 95% CI: 0.96-0.99; p=0.04), see 
Univariable model in Appendix 2. Patients with confirmed Rifampicin mono-resistance and 
those with Rifampicin resistance by GXP only had 9 times the hazards (HR=9.2; 95% CI: 2.2-
38.1; p=0.002) and 12 times the hazards (HR=12.3; 95% CI: 3.0-50.5; p=0.0001) of 
unsuccessful outcomes respectively, compared to those with MDR/XDR/poly-resistant TB. 
Wide CI are noted in the results and this may be due to the small sample. Patients with body 
weight <50kg had 1.5 times higher hazards of unsuccessful outcomes (HR=1.5; 95% CI: 0.9-
2.4; p=0.06) compared to those with weight above 50kg, although the difference was not 
statistically significant at 5% significance level. 
3.9.2 Multivariable Cox regression model: 
Patients with confirmed Rifampicin mono-resistance diagnosis had 8 times the hazards 
(aHR=8.5; 95% CI: 2.0-35.2; p=0.003) and those with Rifampicin resistance by GXP only 
diagnosis had 11 times the hazards (aHR=10.8; 95% CI: 2.6-44.8; p=0.001) when compared to 
those diagnosed with MDR/XDR/Poly TB. This finding of very high hazards of unsuccessful 
outcomes for patients diagnosed by GXP only, may be due to patients having other and 
extensive resistance patterns being treated as though they were MDRTB or RRTB and not 
receiving adequate and appropriate therapy, that led to patients not responding to treatment and 
achieving poor outcomes. There are very wide CI, highlighting the small sample size in the 
study. See Table 3.3 below. 
 
46 
 
Table 3.3:  Predictors of unsuccessful outcomes (died and default combined) among 
patients with DRTB at CMJAH between Jan 2010 to Jan 2014. 
 
 
Predictors 
Univariate analysis Multivariable analysis 
Unadjusted 
Hazard 
Ratio 
P-
value 
95% 
confidence 
Interval 
Adjusted 
Hazard 
Ratio 
P-
value 
95% Confidence 
Interval 
Gender Female Ref 
       
Male 0.778 0.179 0.540 1.122 
    
Age 
category 
<40 years Ref       
  
    
>=40 years 0.767 0.196 0.514 1.146 
    
 
DR-TB 
Diagnosis 
MDR/XDR/Poly TB Ref 
 
  
 
Ref 
 
    
RIF monoTB 9.236 0.002 2.237 38.129 8.460 0.003 2.032 35.219 
RIF resistant by GXP 12.319 0.0001 3.004 50.518 10.865 0.001 2.636 44.774 
 
Weight 
category 
51-59 kg Ref  
   
Ref  
   
<50 kg 1.524 0.066 0.972 2.388 1.561 0.056 0.989 2.463 
60-70 kg 1.007 0.98 0.572 1.774 0.931 0.808 0.523 1.658 
>70 kg 0.931 0.848 0.448 1.934 0.956 0.905 0.455 2.007 
 
3.10 Predictors of unsuccessful outcomes among HIV positive patients: 
Among HIV co-infected patients, negative predictors of default were diagnosis of confirmed 
Rifampicin mono-resistance and those with Rifampicin resistance diagnosed by GXP only 
(see Table 3.4). Being initiated on ART was a positive predictor of default among HIV co-
infected patients. Among the HIV co-infected patients, being initiated on ART reduced the 
hazards of default by 87% (aHR=0.13; 95% CI: 0.05-0.3; p=0.0001) compared to those not 
initiated on ART, when adjusted for DRTB diagnosis. Both groups of patients with 
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confirmed Rifampicin mono-resistance diagnosis and Rifampicin resistance by GXP only 
diagnosis had 11 times higher hazards of default (aHR=10.8; 95% CI:1.4-84; p=0.02) and 
(aHR=10.6; 95% CI:1.4-80.2; p=0.02) respectively, compared to those with MDR/XDR/Poly 
TB when adjusting for ART initiation. Among the HIV co-infected patients, no significant 
predictors of death could be found and this may be due to the small sample size failing to 
show any statistical significance.  
When died and default outcomes were combined and analysed as unsuccessful outcomes (see 
Table 3.5), not initiated on ART had 7.6 times the hazards of unsuccessful outcome 
compared to those initiated on ART (aHR=7.6; 95% CI:4.1-14.1; p=0.0001) adjusting for 
DRTB diagnosis. Patients with confirmed Rifampicin mono-resistance diagnosis and those 
with Rifampicin resistance diagnosed by GXP only had 13 times the hazards of unsuccessful 
outcomes (aHR=12.5; 95% CI:2.9-53.7; p=0.001) and (aHR=12.6; 95% CI:2.9-52.7; 
p=0.001) respectively compared to those diagnosed with MDR/XDR/PolyTB when adjusting 
for ART initiation. 
Table 3.4: Predictors of default among HIV co-infected patients with any RRTB at 
CMJAH between Jan 2010 and Jan 2014. 
 
Variables 
Unadjusted 
Hazard 
Ratio 
P-
value 
95% 
Confidence 
Interval 
Adjusted 
Hazard 
Ratio 
P-
value 
95% 
Confidence 
Interval 
Gender Female Ref 
       
Male 0.711 0.11 0.467 1.081 
    
Age 
category 
<40 years Ref 
     
    
>=40 years 0.640 0.067 0.398 1.031 
    
DR-TB 
Diagnosis 
MDR/XDR/Poly-
resistant TB 
Ref 
   
Ref  
 
    
RIF mono-resistant 
TB 
15.53 0.01 2.128 113.289 10.847 0.023 1.398 84.147 
RIF resistant by 
GXP 
18.19 0.0001 2.501 132.288 10.59 0.022 1.398 80.240 
ART No Ref       Ref 
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Yes 0.344 0.0001 0.196 0.604 0.13 0.0001 0.059 0.288 
 
CD4 
count   
<200 Ref       
    
200-350 0.826 0.592 0.410 1.662 
    
350-500 0.408 0.135 0.126 1.321 
    
>500 0.579 0.452 0.139 2.404 
    
 
 
Table 3.5: Predictors of unsuccessful outcomes (death and default) among HIV co-
infected patients with any RRTB at CMJAH between Jan 2010 and Jan 2014. 
 
 
 
Predictors Univariate analysis Multivariable analysis 
Unadjusted 
Hazard Ratio 
P-
value 
95% conf 
interval 
Adjusted 
Hazard 
Ratio 
P-
value 
95% conf 
interval 
Gender             Female Ref 
       
Male 0.778 0.179 0.540 1.12161 
    
Age 
category 
<40 years Ref         
  
    
>=40 years 0.767 0.196 0.514 1.14605 
    
ART Yes Ref 
   
Ref 
   
No 2.639 0.0001 1.598 4.359 7.586 0.0001 4.074 14.126 
Diagnosis 
DR-TB 
MDR/XDR/Polyresist Ref 
 
    Ref 
 
    
RIF mono resistance 9.236 0.002 2.237 38.1294 12.505 0.001 2.910 53.743 
RIF resistant on 
GXP 
12.319 0.0001 3.004 50.5177 12.563 0.001 2.994 52.717 
Weight 
category 
50-59 kg Ref 
   
  
   
<50 kg 1.524 0.066 0.972 2.388 
    
60-70 kg 1.007 0.98 0.572 1.77387 
    
>70 kg 0.931 0.848 0.448 1.9341 
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4 CHAPTER 4: DISCUSSION 
4.1 Introduction: 
In the study we investigated what the RRTB treatment outcomes were, in an ambulatory urban 
setting, what the predictors of the unsuccessful treatment outcomes were and the time to 
unsuccessful outcomes. We also investigated the difference in outcomes in HIV co-infected 
compared to HIV uninfected patients. 
The study observed a very high percentage of new patients diagnosed who had no history of 
prior TB disease, highlighting a high primary resistance pattern occurring and showing that 
transmission of DRTB in the community setting is higher and may be underestimated. There 
were very few patients diagnosed with MDRTB and XDRTB (only one patient with XDRTB). 
This may be the reason why we could not demonstrate the association of more extensive drug 
resistant TB with unsuccessful treatment outcomes as previously reported in other studies. 
Literature had shown that the more the baseline resistance patterns detected for example if 
diagnosed with pre-XDR and XDRTB, these patients were more likely to have poor treatment 
outcomes.[34]  Sputum GXP testing diagnosed more patients with DRTB compared to sputum 
smear testing alone, highlighting the importance of GXP testing in all suspected TB patients.[2] 
4.2 DRTB Treatment outcomes 
The results from this study showed an overall poor successful outcomes (5.1% cured and 14% 
completed treatment), a proportion smaller than ever reported in any other study where 
decentralization of DRTB care was implemented. [4, 24, 34, 36]. Many studies report only MDRTB 
treatment outcomes, whereas this study reported any RRTB outcomes, showing paucity of 
studies investigating any RRTB treatment outcomes. No studies reported on clinic-based 
ambulatory treatment outcomes but community-based and centralized hospital DRTB 
outcomes were reported. The rate of successful DRTB outcome in this study was also worse 
than that reported by the World Health Organization for SA in their 2017 report, with success 
rates of 54% and 27% for MDR/RRTB and XDRTB respectively. [33] Two meta-analysis 
comparing community-based and traditional hospitalization of DRTB patients have reported 
successful outcomes above 60%. [6, 32] The meta-analysis by Williams et al included 16 studies 
from different parts of the world with high TB burden and South African data was included in 
their analysis. [32] The difference in successful outcomes seen in this study and the studies 
mentioned that reported higher success rates, may be due to the difference in HIV/TB co-
50 
 
infection rate. This study reported a very high HIV/TB co-infection rate compared to the low 
co-infection rates reported in many of these studies. A study that reported outcomes of DRTB 
in a high HIV/TB co-infection rate in SA context had lower rate of co-infection compared to 
this study’s observation. Farley et al reported HIV/TB co-infection rate of 38%, much lower 
rate than observed in this study. [14] It was routine in this study for patients presenting with any 
form of TB to be offered HIV counselling and testing. This shows consistent adherence of 
treatment guidelines for patients presenting with either HIV or TB to check for the other disease 
as they often present together. In SA TB patients co-infected with HIV had better ART 
coverage compared to previous years, with 88% of patients on ART according to the 2017 
WHO TB Report.[33] Integrated TB and HIV care services have shown to improve treatment 
outcomes in studies.[8, 9, 19] 
Another study observed similar poor outcome results, they assessed similar ambulatory care 
DRTB treatment outcomes in a slum setting in India, which showed successful outcome rate 
of 22% in a similar population of HIV/TB co-infected patients. [36] Another study in SA with 
similar high HIV prevalence setting reported better success rate of 46% in MDRTB treatment 
outcomes. [14] In our study we observed a very low cure rate of 5.3%, and this low rate may be 
due to patients not able to produce sputum at the end of treatment to confirm cure or that 
collection of sputum did not occur for whatever reason and hence they were classified at the 
end of treatment as completed treatment outcome, this leading to an underestimation of cured 
patients. In a low-income setting in Peru, ambulatory community based therapy for MDRTB 
patients reported impressive cure rate of 83%. [24] The study associated the high success rate 
for these patients with inclusion of PZA and ETO in their treatment regimen. In this study we 
observed that there was a high proportion of patients  in whom Rifampicin resistance diagnosed 
on GXPert was never confirmed. The high proportion of unconfirmed GXPert Rifampicin 
resistance may account for the poor outcomes seen, as this could have been poly-resistant TB 
or XDRTB patients who were treated as though they had RRTB, as there was no culture nor 
LPA confirmation done to ascertain proper diagnosis and classification of these patients and 
appropriate therapy for them. 
The proportion of deaths observed in this study was slightly lower than that reported in a meta-
analysis by Weiss et al which reported 13% deaths. [6] The observed deaths in our study was 
much lower than seen in two other studies with high HIV/TB co-infection rate, with death rates 
ranging from 17% to 25%. [14, 36, 45]  Seung et al showed that mortality remained high in 
HIV/MDRTB co-infected patients in a study done in Lesotho in a community-based care 
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model. [47] Deaths remained similar to a study from a low income setting in Peru at 8%. [24] In 
another study with HIV/TB co-infection high burden setting in South Africa where community 
based treatment of DRTB was done, they reported better successful outcomes of 52% although 
the deaths were slightly higher than seen in our study at 13%. [4] Data has shown that the 
proportion of deaths was higher among TB patients who were co-infected with HIV than 
uninfected patients, although ART initiation improved survival in these co-infected population 
in a South African study. [8] The proportion of deaths observed in this study was much lower 
than that reported in a centralized care model (which also had high HIV/TB co-infection rate) 
seen at the referral centralized care model, which found death rate of 23% in a study reported 
by Umanah et al. [40] This difference may be due to the fact that the centralized care model had 
patients who were more sick warranting hospitalization, with presence of cavitatory lesions 
and other co-morbid conditions. We observed that there was no statistical difference in the 
proportion of those who died when stratified by HIV status in this study, this finding was 
contrary to findings in few studies showing poor survival of HIV co-infected patients. [4, 8, 14] 
The difference in deaths between HIV co-infected and those uninfected, observed in our study 
may be due to the high ART coverage. HIV/TB co-infection had no influence on early 
outcomes in patients with MDRTB in a study done in Botswana of patients receiving 
ambulatory DRTB care, the study showed no difference in proportion and time to sputum 
conversion when HIV positive were compared to HIV negative patients. [42] Padayatchi et al 
reported an 86% reduction in mortality when ART were initiated early in MDRTB patients on 
treatment. [13] The poor outcomes observed in our study with a high TB/HIV co-infection 
burden and a very high ART coverage of 83% conflicts with data reported by Abdool-Karim 
et al showing that integrated TB and HIV care improved survival of TB patients, although their 
patients had drug sensitive TB. [8] 
Our study reported very high proportion of defaulting, with 28% of the patients having 
defaulted from therapy. A systematic review and meta-analysis by Weiss et al has shown a 
lower defaulter rate of 15%, from community-based treatment models. [6] Cox et al also 
reported slightly higher defaulter rate of 31% in a SA peri-urban community-based DRTB 
treatment setting with a high HIV burden. [4] They concluded that this may be due to poor 
tolerability and the long duration of DRTB treatment. [4] Severe adverse events were common 
within the first six months of therapy in a study by Schnippel et al [44] and this may increase the 
risk of defaulting and death within DRTB and HIV co-infected populations. Isaakidis et al 
reported similar high defaulter rate of 26% in an ambulatory care model in a HIV co-infected 
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population in a low socio-economic setting in India. [36] A study by Shean et al also reported a 
similar high defaulter rate (29%), although this study had very low HIV/TB co-infection rate 
of 9% and was not an ambulatory nor a community-based care model. [38] 
We also observed a high proportion of transfer out, which is much higher than transfer out seen 
before in other studies in SA, ranging between 6% and 12%. [38, 40] Umanah et al study had very 
low transfer outs as this was a centralized DRTB site and a referral DRTB hospital, as patients 
will not have transferred elsewhere. [40] A meta-analysis by Johnston et al showed even lower 
transfer out rate of 2%. [35] In this study the high transfer rates occurred due to a high referral 
rate to a centralized DRTB treatment and referral centre, Sizwe Hospital. Whenever patients 
needed hospitalization for whatever reason, either when their sputum smear was positive or 
when they developed XDRTB or poly-resistance TB and needed to be referred and managed 
in a centralized facility, as the ambulatory care model in this study did not treat patients with 
pre-XDRTB, XDRTB or smear positive sputum after DRTB treatment was initiated.  
No treatment failures were observed in this study, this was also reflected in other studies where 
DRTB treatment failure rates were low between 3% and 10%. [14, 32, 36, 40] Treatment failure was 
high in centralized compared to community treatment models as seen in a systematic review 
and meta-analysis by Williams et al. [32] The lack of failures in this study which showed less 
favourable outcomes may be due to early referral of patients to a centralized hospital whenever 
sputum conversion was not being achieved. 
4.3 Time to unsuccessful outcomes (default and death) 
Patients in this study defaulted and died very early in the study (within the first 3 to 4 months) 
after initiating DRTB treatment. Survival times for death outcome seen in this study are better 
compared to those seen in a study by Isaakidis et al with even a shorter survival time of 27 days 
in a HIV/TB co-infected population in slum Indian setting. [36] Early severe adverse events have 
been reported to occur within the first six months of DRTB therapy and associated with 
defaulting and death in patients receiving DRTB treatment in study reporting severe adverse 
events to DRTB treatment in a high HIV burden setting. [44] In patients with HIV co-infection, 
ARVs would further contribute due to overlapping of such severe adverse events to both the 
DRTB treatment and the ARVs. This might have contributed to the high defaulter rate in this 
study as majority of the patients were on ART as well, even though we did not seek to 
investigate when ARTs were initiated in conjunction with the DRTB drug initiation (before or 
after DRTB treatment), as Umanah et al investigated. A study by Gandhi et al, suggested that 
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deaths from MDRTB in HIV-infected patients were very high and usually occurred within the 
first 30 days after diagnosis. [46] Hoa et al has reported that half of the deaths occurred within 
the first 2 months after starting therapy, and the median time to default in China and 
Cambodia/Vietnam was 2 and 3 months respectively. [37] In another study done in Estonia, the 
median time to death was longer than we observed at 5 months. [28] Whereas a Russian study 
reported even shorter survival time with median time to death of just over a month. [43] Default 
happened throughout the study as reported by Moyo et al, contrary to our findings of very early 
default. [45] The reason for early default and death within the first 6 months after treatment 
initiation may be due to overlapping adverse events to both ARVs and anti-DRTB drugs, which 
were seen within the first 6 months of therapy in a study done in DRTB clinics with a high HIV 
burden. [44] 
4.4 Predictors of unsuccessful outcomes (default and death) 
The study did not have enough power to elucidate predictors of death due to small sample. 
Literature has described many predictors of death in patients with DRTB with or without HIV 
co-infection. A meta-analysis by Johnston et al reported being male a negative predictor of 
successful treatment outcomes. [35] Other predictors of death were low baseline weight <45kg 
and <60kg, which increased the hazards of death as seen in a South African study with high 
HIV prevalence. [14] This study failed to demonstrate low weight as a predictor of unsuccessful 
outcomes. We observed data that also showed low BMI was a negative predictor of death in a 
study by Mitnick et al. [24] In this study we couldn’t analyse BMI as there was no recorded 
height for any of the patients in this data. Low baseline weight <45kg was also a negative 
predictor of failure outcome in the same study by Farley et al. [14] Age >35 years was also 
associated with a high hazard of death in another South African study by Moyo et al. [45] Being 
HIV positive was reported to have higher hazards of death, these patients had twice the odds 
of dying compared to the HIV uninfected patients in a study by Farley et al, although in another 
study in DRTB within a high HIV burden setting, infected patients had up to 86% less chances 
of death when started on ARVs. [14, 13]  Studies reporting DRTB treatment outcomes in HIV co-
infected patients have shown lower treatment success compared to studies with no HIV co-
infection. [52-58] This emphasized what the guidelines advocate for, that when patients are co-
infected with TB and HIV, initiation of ARVs for all these patients at the correct timing needed 
to improve their treatment outcomes. A meta-analysis by Johnston et al also found XDRTB 
diagnosis to be a predictor of poor outcomes. [35] This finding conflicts with our observation in 
this study which found RMRTB and RRTB on GXPert only (unconfirmed RRTB) to have 
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higher hazards of unsuccessful outcomes compared to MDRTB, XDRTB and poly-resistance 
TB diagnosis. The results also contradicted those reported by Brust et al, that showed that the 
more the baseline drug resistance and prior TB the higher the risk for treatment failure. [21] 
These results may have resulted due to the small sample and very low number of MDRTB, 
poly-resistant TB and XDRTB patients in the study, that may have led to failure to detect any 
association with unsuccessful outcome as previously reported. 
The following predictors were associated with default in this study: RMRTB, Rifampicin 
diagnosed by GXP only and baseline weight loss. Weight loss has been found in other studies 
to be a risk factor of poor outcomes generally in DRTB patients. [14, 24] Weight loss has been 
reported as one of the key presenting symptoms of severe TB and HIV disease manifestation, 
and clinicians need to assess and correct any baseline weight loss with nutritional support to 
improve survival of these patients. A meta-analysis by Weiss et al failed to identify any 
predictors of successful outcomes. [6] The high defaulter rate within the first few months after 
commencing DRTB treatment may be associated with the injectable phase of intensive 
treatment and overlapping side effects from both anti-TB drugs and ARVs as seen in a study 
reporting adverse events in DRTB co-infected patients. [44] With a push towards shorter courses 
of treatments to improve adherence and completion of therapy, caution is still needed to address 
factors that impact negatively on early defaulting, as these factors may result in poor outcomes 
even with proposed shorter treatment regimen. 
4.5 Predictors of unsuccessful outcomes among HIV co-infected patients 
There was no statistical difference in proportions of those who died and defaulted when 
stratified by HIV status, except there was a significant difference in the proportion of the 
transfer out outcome, showing that a high proportion of HIV co-infected patients were 
transferred out (75%) compared no HIV uninfected in this study. This finding was contrary to 
those found in few studies showing a difference and poor survival of HIV co-infected patients. 
[8, 14, 46]  Cox et al study reported earlier programmatic years and the poor survival of HIV co-
infected patients may be due to low ARV coverage during that time period. [4] Among HIV 
positive patients in this study, being initiated on ART was a positive predictor of default. 
Initiated on ART had 90% less hazards of default than not initiated on ART. Data from other 
studies support this finding. Initiation of ART during anti-TB treatment in patients with MDR-
TB was associated with 86% reduction in mortality in a SA study. [13] In two systematic reviews 
and meta-analysis in DRTB/HIV co-infected patients supported this finding that ARV 
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initiation improved MDRTB outcomes of these patients. [15, 35] Although in a study by Umanah 
et al, if HIV infected patients initiated ARVs before commencement of their DRTB treatment, 
the odds of mortality was higher than ARVs initiated after commencement of DRTB treatment. 
[41] This is surprising as ARVs should be protective, but they attributed their finding to poor 
adherence leading to virological failure among these patients then resulting in IRIS.   
Among HIV positive patients, the positive predictors of default were being initiated on ART 
and age >40 years. Patients aged >40years had 40% less hazards of default compared to those 
aged <40years. This finding supports that in Moyo et al, where patients aged 15 - 25 years had 
higher hazards of defaulting in a community care model with high HIV co-infection setting. 
[45] There is more data supporting better adherence to treatment in older adults compared to 
younger adults who are HIV positive. [49 - 51] This may also support better adherence of these 
older patients to their anti-TB drugs when co-infected with HIV.  
Other predictors of default were DRTB diagnosis of RMRTB and Rifampicin resistance on 
GXP only. This findings conflict with that reported from other studies that showed that if there 
was more extensive baseline resistance like pre-XDRTB and XDRTB, there were higher 
hazards of poor treatment outcomes than having mono-resistance patterns like RMRTB. [21, 34, 
35] Again these results are due to small sample in the study and due to the very low number of 
MDRTB, poly-resistant TB and XDRTB patients, that may have led to our failure to detect any 
association with unsuccessful outcome as previously reported. The study was not powered to 
show predictors of death for HIV and TB co-infected patients in this study, due to the small 
sample size. 
4.6 Potential study biases 
4.6.1 Collection of exposure and outcome data 
This study collected retrospective routine clinic data and have not measured all relevant factors. 
The date of DRTB diagnosis was not recorded in the data and hence could not analyse time 
from diagnosis to initiation of treatment for all patients. Other important factors like serial 
sputum culture results could have assisted in assessing sputum conversion times in the study. 
Height was not collected for 100% of the patients at baseline and hence could not calculate 
BMI.  HB had a lot of missing data and where it was recorded, there were incorrect readings 
of the readings and could not be analysed as a predictor of poor outcomes.  CXR findings were 
only recorded in a few patients and could not assess its impact on the outcomes.  
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Information bias was avoided by presenting blood results of TB, HIV, CD4 count from the 
referral clinics/hospital and where these laboratory tests were unavailable, they were collected 
to ascertain diagnosis to minimize misclassifying especially HIV status. DRTB diagnosis of 
Rifampicin Resistance on GXP without any confirmation by LPA/DST may have resulted in 
misclassification of DRTB diagnosis as these patients might have been either MDR/XDR/Poly-
resistant TB had confirmatory tests (LPA/culture) been done.  
Outcomes for the study were measured to avoid misclassification bias, as cured outcome was 
based on laboratory confirmation of consecutive negative cultures and DST, and all patients 
were followed up for a year after treatment was completed to ascertain successful outcomes. 
Tracing of patients who default any appointment date was strict and patients were only 
classified as defaulted after 2 consecutive months. Misclassification of outcome may have 
occurred if patients had died at home and the death couldn’t be ascertained by contacting the 
family/relatives of patients by the clinic, then the patients would be misclassified as defaulted.  
There was only one patient in the study diagnosed with XDRTB and few only diagnosed with 
poly-resistant TB, therefore these were merged together with MDRTB category, this may have 
introduced some biasness were only few patients in the study diagnosed with MDRTB and they 
XDRTB 
4.6.2 Residual confounding and missing data of some of the exposure variables 
Exposure variables were correctly stratified to limit possible confounding. Univariable analysis 
were done for unsuccessful outcomes, defaulted and died and included only those factors with 
a p-value<0.1 into the multivariable models in order to adjust for other factors to reduce 
residual confounding. Only factors with p-value<0.05 were considered as significant predictors 
of default, died and unsuccessful outcomes. The association found between the exposure 
variables and the outcomes was not due to chance. 
 This study collected retrospective routine clinic data and have not measured all relevant factors 
of interest. The date of DRTB diagnosis was not recorded in the data and hence could not 
analyse time from DRTB diagnosis to initiation of treatment for all patients. Other important 
factors like serial sputum culture results could have assisted in assessing sputum conversion 
times in the study. Height was not collected for all the patients at baseline and hence could not 
calculate BMI nor analyse the impact of BMI on our outcomes in this study.  HB had a lot of 
missing data and where it was recorded, there were incorrect readings of the variable and could 
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not be analysed as a predictor of poor outcomes.  CXR findings were only recorded in a few 
patients and could not assess its impact on the outcomes.  
4.7 Study limitations 
As this was a retrospective study, some of the observations in the data were missing for 
example data on co-morbidities, CD4 counts, VL, height, and weight. This may have affected 
the statistical power to detect such variables as significant predictors during the multivariable 
analyses. Failure to analyze VL for HIV positive patients and HB due to these variable data 
completely missing. The sample size was small and hence not powered enough to show an 
association between unsuccessful outcomes and the predictors. The small sample of extensive 
DRTB patients may have resulted in failure to show an association with unsuccessful outcome. 
The quality of data was not of a good standard.  
The study lacked data for inpatient (hospitalised) treatment outcomes and also lacked the 
opportunity to treat patients within their communities in order to compare these models with 
the clinic based ambulatory treatment outcomes within this study. There was a lack of data on 
DRTB drug regimen initiated on individual patients to assess the impact of different regimens 
on outcomes. In earlier clinic years, before standardized DRTB guidelines were developed, 
clinicians would initiate individualized as opposed to standardized regimens, but this was not 
recorded to allow comparison between standardized and individualized therapy. Use of 
baseline variables for example CD4 count and weight may not give a true picture of association 
with the outcomes as these are time-varying variables and may improve with time. This may 
be the reason low baseline CD4 count could not show any association with poor outcomes in 
the study as these outcomes occur over a period of time. 
4.8 Study strengths 
The exposure variables were collected for this study before the outcome occurred and this 
ensured temporal relationship between the exposure variables and the outcomes. The study not 
only assessed MDRTB but any Rifampicin resistance including Rifampicin mono-resistance, 
poly-resistant TB, pre- and XDRTB and MDRTB, and this included patients diagnosed by 
GXP alone and not confirmed by either LPA or DST. 
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4.9 Generalizability 
This study may not be generalizable to other settings due to it being in an urban highly mobile 
population setting in the city of Johannesburg, and may not be generalizable in rural or peri-
urban settings. The DRTB/HIV co-infection rate is the study is very high and may not be 
generalizable in low HIV prevalence settings, and the results of this study must be interpreted 
with caution in other settings. The ART coverage of this study was also very high and in 
settings where ART coverage is still low, the results must be interpreted with caution. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
59 
 
5 CHAPTER 5: CONCLUSION & RECOMMENDATIONS 
 
5.1 Conclusion 
In conclusion, this study in an ambulatory urban setting showed no better successful outcomes 
with a high defaulter rate when compared to rural or peri-urban community-based care models 
and other ambulatory care models for DRTB patients in a high HIV burden clinic. There were 
comparable deaths and no treatment failures seen in the study. Death and defaults happened 
early within the first 6 months which fell within the intensive phase (injectable phase) of DRTB 
therapy, further supporting the need for alternative short course non-injectable treatments. ART 
initiation among the DRTB and HIV co-infected patients reduced the hazards for unsuccessful 
outcomes (both death and default). Median survival time for unsuccessful outcomes were very 
short falling within the intensive phase of DRTB therapy. Predictors of default were RMRTB, 
Rifampicin diagnosed by GXP only and baseline weight loss. Positive GXP results showing 
Rifampicin resistance need to be There were no predictors of mortality found in this study. For 
a subgroup of HIV co-infected patients, being initiated on ART was associated with 90% less 
hazards of defaulting. Age category >40 years had less hazards of defaulting among HIV co-
infected patients and reduced the hazards of default by 60%. Confirmed RMR-TB and 
unconfirmed Rifampicin-resistance diagnosed on GXP were also predictors of default among 
HIV co-infected patients. There was no difference found in proportions of successful and 
unsuccessful outcomes between HIV co-infected and HIV negative patients.  
5.2 Recommendations 
In summary, the high defaulter rate within the first few months after commencing DRTB 
treatment impacts negatively on the control of DRTB, hence efforts to improve defaulting from 
care are needed. Addressing factors associated with defaulting is crucial in DRTB clinics to 
curb transmission of DRTB in the community. All Rifampicin resistant results on GXP need 
immediate confirmation by LPA and culture/DST, to avoid treating DRTB patients 
inappropriately. Clinicians need to follow DRTB management guidelines for diagnosis and 
treatment, as these patients may be XDRTB or Poly-resistant TB who are treated as though 
they were RMRTB or MDRTB cases. Integrating DRTB and HIV management services has 
positively impacted on the outcomes of DRTB in HIV co-infected patients, a programme that 
needs to be broadly implemented and supported by both government and non-governmental 
institutions. ART initiation for all DRTB patients is needed at appropriate timing to improve 
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survival of HIV co-infected patients. Tracing of transfer out to determine final outcomes is 
needed, to avoid underestimation of successful outcomes in national TB programmes. The 
study confirms that starting ART in DRTB and HIV co-infected patients will result in better 
retention within the health care system and in turn improve the treatment outcomes for patients 
DRTB and HIV co-infected patients. The early deaths and defaults highlight the importance of 
close monitoring of these patients during the intensive phase of therapy, intensifying adverse 
event monitoring and reporting by both patients and clinicians. This echoes the need for short-
course treatment regimen, without injectable treatments. With a push towards short course 
treatment regimen to improve adherence and treatment outcomes, caution is still needed to 
address factors that impact negatively on early defaulting and deaths as this will impact 
negatively on any of these short treatment regimen.   
5.3 Potential areas of further research 
Explore further why clinicians were not confirming positive sputum GXPert results and seek 
to understand their knowledge gaps in treating DRTB even when DRTB management 
guidelines were available. A more powered study with a larger sample size should be 
conducted to further explore and understand why patients defaulted early during the treatment 
journey. Newer treatment regimens aim to decrease early defaulting in these patients, lack of 
understanding of predictors of early default may see even these new short duration treatments 
not being successful as patients dropped out of care as early as 1 to 6 months after DRTB 
treatment was started. 
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7 Appendices: 
Appendix 1: Plagiarism declaration form  
 
70 
 
 
Appendix 2: Bivariate Cox regression analysis of predictors of unsuccessful DRTB 
treatment outcomes (death and default) at CMJAH 2010 - 2014 
Independent variables Hazard Ratio P-value 95% CI 
Gender Female 1 (Base) 
  
Male 0.778 0.179 0.540 1.122 
Age category <40 years 1  (base)       
>=40 years 0.767 0.196 0.514 1.146 
HIV status Negative 1 (base)     
Positive 1.095 0.752 0.625 1.916 
Diagnosis patient 
category 
New 1  (base)       
reRx_reg1 1.280 0.234 0.852 1.922 
reRx_reg2 1.413 0.559 0.444 4.494 
ART No 2.639 0 1.598 4.359 
Yes 1  (base) 
   
Bactrim prophylaxis No   1  (base)     
Yes 1.414 0.206 0.827 2.417 
Refering facility PHC 1 (base) 
  
Private facility 0.474 0.459 0.066 3.421 
CMJAH wards/OPD 1.123 0.741 0.565 2.230 
Other hospital 1.367 0.425 0.634 2.947 
Employment Employed 1  (base)       
Unemployed 1.641 0.167 0.813 3.309 
Unknown 1.516 0.199 0.804 2.858 
Education Education 1 (base) 
  
No Education 1.199 0.565 0.645 2.228 
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Nationality South African 1 (base)     
Non-SA 1.661 0.388 0.525 5.255 
cd4_grp  <200 1 (base) 
  
200-350 0.753 0.361 0.410 1.383 
350-500 0.470 0.106 0.188 1.174 
>500 0.416 0.224 0.101 1.709 
diagnosis DR-TB MDR/XDR/Polyresis. 1 (base)     
     
RIF mono-res.. 9.236 0.002 2.237 38.129 
RIF resistan.. 12.319 0 3.004 50.518 
          
Weight category <50 kg 1.524 0.066 0.972 2.388 
50-59 kg 1  (base) 
   
60-70 kg 1.007 0.98 0.572 1.774 
>70 kg 0.931 0.848 0.448 1.934 
 weight 0.981 0.041 0.963 0.999 
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Appendix 3: Test of proportional assumption 
 
Test of proportional-hazards assumption table 
Factors rho chi2 df P-value 
Gender 0.04654 0.2 1 0.658 
Age category       -0.02517 0.06 1 0.811 
ART            -0.13295 1.62 1 0.2025 
Diagnosis DRTB   -0.01587 0.02 1 0.8996 
Weight category        0.0995 0.97 1 0.3247 
global test 3.08 5 0.6881 
No violation of the proportional hazard assumption was observed 
 
 
Appendix 4: Goodness of fit for the final model 
 
The hazard function follows a 45degree line; we can assume the model fit the data well 
 
0
1
2
3
4
0 1 2 3 4
Cox-Snell residual
Nelson-Aalen cumulative hazard Cox-Snell residual
73 
 
Appendix 5: Written permission from the CMJAH on conducting research 
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